Pharma Stock Jumps After Signing Agreement to Acquire 55% Stake in Swiss MedTech Firm

Synopsis: Alkem Laboratories’ subsidiary signed a supplementary agreement to acquire a 51-55% stake in Switzerland-based Occlutech Holding AG, strengthening its global medical technology business and international presence.

This Mid-Cap Pharma Stock, engaged in the research, development, manufacturing, and marketing of pharmaceutical formulations, generic medicines, active pharmaceutical ingredients (APIs), and healthcare products, jumped 2 percent after signing an agreement to acquire up to 55 percent stake in Swiss MedTech Firm Occlutech.

With a market capitalization of Rs. 65,304.01 crores, the share of Alkem Laboratories Limited has reached an intraday high of Rs. 5,529.50 per equity share, rising nearly 1.99 percent from its previous day’s close price of Rs. 5,421.65. Since then, the stock has retreated and is currently trading at Rs. 5,461.80 per equity share. 

Reason Behind the Surge:

Alkem Laboratories Limited has announced that its wholly owned subsidiary, Alkem Medtech Private Limited, has signed the First Supplementary Agreement to the Share Purchase Agreement for the proposed acquisition of at least 51 percent and up to 55 percent stake in Occlutech Holding AG, a Switzerland-based medical device company. The supplementary agreement was executed on June 26, 2026.

The acquisition is part of Alkem’s strategy to expand its presence in the global medical technology business. The transaction, which follows the agreements signed earlier in February and March 2026, is expected to strengthen the company’s international footprint and diversify its healthcare product portfolio.

Global Presence:

Alkem Laboratories is one of India’s leading pharmaceutical companies and ranks as the 5th largest pharma company in the country in terms of market share. The company has a global presence across more than 40 countries, supported by 4 R&D centres, 18 manufacturing facilities in India and the US, including 6 USFDA-approved plants.

The company has a strong distribution network with 7 central warehouses, 73 sales depots and CFAs, and over 8,800 stockists. Backed by a workforce of more than 21,000 employees, Alkem continues to strengthen its domestic and international presence through innovation, manufacturing excellence, and an extensive supply chain.

Company Overview:

Alkem Laboratories Limited is engaged in the research, development, manufacturing, and marketing of branded generic medicines, generic drugs, and active pharmaceutical ingredients (APIs). The company has a strong presence in therapeutic segments such as anti-infectives, gastrointestinal, pain management, vitamins, and chronic therapies. 

The company operates multiple manufacturing facilities that cater to both domestic and international markets, with products sold in over 40 countries. Alkem also has a growing presence in the medical devices and biotechnology segments through its subsidiaries.

Recent Quarter Results:

Coming into financial highlights, Alkem Laboratories Limited’s revenue has increased from Rs. 3,144 crore in Q4 FY25 to Rs. 3,603 crore in Q4 FY26, which has grown by 14.60 percent. The net profit has decreased by 22.05 percent from Rs. 322 crore in Q4 FY25 to Rs. 251 crore in Q4 FY26.

Alkem Laboratories Limited’s revenue and net profit have grown at a CAGR of 11 percent and 9 percent, respectively, over the last five years.

In terms of return ratios, the company’s ROCE and ROE stand at 21.2 percent and 18.9 percent, respectively. Alkem Laboratories Limited has an earnings per share (EPS) of Rs. 193, and its debt-to-equity ratio is 0.15x.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock Jumps After Signing Agreement to Acquire 55% Stake in Swiss MedTech Firm appeared first on Trade Brains.